Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Ipilimumab + Nivolumab in Melanoma
NCT06566391Phase 2Active, not recruiting
- Sponsor
- European Institute of Oncology
- Start
- Mar 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by European Institute of Oncology. Primary endpoint: Pathological Complete Response. Started Mar 2019; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06566391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566391.